Official media partner of business and marketing eventsEvents calendar
VANTAGE52

Loading market data

Entrepreneurs

Oura Agrees to Pay $625 Million for Counsel Health, 17 Times What It Raised

Dr Muthu Alagappan’s AI primary care startup sells for cash after raising $36 million. For Oura, which shelved a $2.2 billion listing on 29 September, the deal would take a wellness ring company into delivering medical care.

Collage at night with a smart ring on a sleeping hand, a phone showing the Oura and Counsel logos, a doctor in silhouette reading a tablet, a blank prescription pad, a San Francisco cable car and sandstone and black paper strips.
Illustration by VANTAGE52
VANTAGE52 Editorial · Edited by VANTAGE52 Editorial

Oura, the smart ring maker, agreed on 10 November to buy Counsel Health, a startup that pairs a medical AI with its own doctors, for $625 million in cash. The price is subject to purchase price adjustments and customary closing conditions, and the deal is expected to close before the end of 2026.

For Counsel’s founder and chief executive, Dr Muthu Alagappan, it is a cash exit at about 17 times the $36 million the company disclosed raising in two rounds. For Oura, which postponed a listing of up to $2.2 billion on 29 September, it is a step from tracking health into delivering medical care.

Oura, based in San Francisco with its EU headquarters in Oulu, Finland, announced the deal alongside preliminary, unaudited results. Revenue rose 153% to $533 million in the fiscal fourth quarter to 30 September, with adjusted EBITDA of $87 million, and reached about $1.75 billion for the year, up 92%.

What Oura Is Buying

Counsel’s service starts with an AI that answers health questions and interprets lab results. Users can bring in one of its board-certified physicians, who can diagnose, prescribe, order tests and make referrals when appropriate. Oura says the service is not meant for emergencies.

The two companies have worked together since May, when Counsel became available inside the Oura app through a partnership. According to Oura’s announcement, Counsel’s doctors can see a member’s ring data and past conversations only with permission, and more than half of Counsel users in the Oura Labs programme have shared that data with their physicians.

Counsel will keep its other customers. It sells to health plans, health systems, consumer health companies and employers, and will go on serving people who do not wear a ring. “Oura tells members what’s happening in their bodies, and Counsel helps them act on it,” said David Shuman, Oura’s executive chairman.

A Cash Exit at About 17 Times Capital Raised

Counsel raised an $11 million seed round led by Andreessen Horowitz in October 2024 and a $25 million Series A led by Andreessen Horowitz and GV in October 2025, according to the company. Digital Health News also put its total funding at $36 million. On those figures, Oura is paying about 17 times the capital invested, less than 13 months after the Series A.

The multiple is a rough guide. How the proceeds divide between founders, employees and investors has not been disclosed, and the price will be adjusted at closing. What is clear is the form. The announcement describes the consideration as cash, so Counsel’s backers do not have to wait for Oura to list before they can realise their gain.

The exit comes in a year when AI companies took 64% of global venture funding in the third quarter. Counsel is a service business in which software does the first part of the work and licensed doctors the rest, a model investors are also funding in law, as Legora’s $550 million raise for legal AI showed.

Why a Ring Maker Wants Doctors

Oura’s own prospectus, filed with the US Securities and Exchange Commission on 3 September, shows the gap Counsel fills. It describes Oura Advisor, the app’s AI assistant, as designed to help members make sense of their data “rather than prescribing or delivering medical care”, and names the Counsel partnership as the route to licensed physicians. Buying Counsel brings that clinical step inside the company.

There is a commercial logic too. Hardware still produces most of Oura’s revenue, and memberships made up about 20% of sales, TechCrunch reported from the filing. Counsel adds a services business with health plan and employer customers to a company that has so far earned its money mainly from rings.

Oura has been building towards this. The S-1 lists blood tests through Quest, glucose biosensors in partnership with Dexcom and care services through Counsel as products that layer data and services on to the ring, with the stated aim of raising the lifetime value of each member.

The Listing That Was Shelved in September

Oura postponed its flotation on 29 September, citing “uncertainty in the IPO market”, after seeking to raise up to $2.2 billion, TechCrunch and Healthcare Dive reported. The postponement was indefinite. Tom Hale, the chief executive, said at the time that the company had “the luxury of choosing our moment”.

Paying cash still matters for a company in that position. The prospectus showed $371.8 million of cash and $380.1 million of debt at 30 June, and Oura has not said how it will fund the $625 million. TechCrunch reported that Oura was valued at about $11 billion when it raised $900 million in a round led by Fidelity in October 2025.

The fourth-quarter profit figures help the case Oura would make at a second attempt, but they are not final. The company says the results are preliminary and unaudited and may change as it completes its year-end close and audit.

Where Regulation and Liability Sit

Oura built its ring business under wellness rules. Its prospectus says it markets certain products as general wellness products that it believes are not actively subject to FDA medical device requirements, and warns that a different view from the agency would bring costly obligations. It also says HIPAA, the US health privacy law, does not generally apply to most of its operations, although it acts as a business associate for some healthcare partners.

Counsel sits on the other side of that line. Its diagnoses and prescriptions come from physicians in a medical group it says is licensed in all 50 states, and Dr Alagappan says the company keeps “physicians in the loop for clinical decisions”. Updated FDA guidance issued on 6 January, as summarised by the law firm Foley & Lardner, still bars wellness products from making medical or clinical claims.

Neither the announcement nor Oura’s blog says how clinical responsibility will be divided between Counsel’s AI, its doctors and Oura once the businesses combine, or whether any part of the AI needs regulatory clearance. The next fixed point is closing, expected by 31 December. After that, Oura’s audited results for the year to September will show what a second listing attempt would rest on.

Tags

Key Concepts

Share this story

Sources

Where the reporting above comes from. Follow these to check the figures and statements for yourself.

More From Business

Choose which cookies we may use. You can change this at any time from “Manage cookies” at the foot of every page.